Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies

Analyse de l'Effet Des caractéristiques de concentrés Plaquettaires Sur le Rendement Transfusionnel Chez Les Patients Ayant Une hémopathie Maligne et bénéficiant de Transfusions Plaquettaires à Titre Prophylactique

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02885038

Acronym

TCP

Enrollment

1101

Registered

2016-08-31

Start date

2015-01-31

Completion date

2016-03-31

Last updated

2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hodgkin Disease, Lymphocytic Leukemia, Lymphoma, Multiple Myeloma

Keywords

Platelet Transfusion

Brief summary

Platelet concentrates (PCs) characteristics, such as storage duration, ABO compatibility, dose and source, may have an impact on transfusion responses and outcomes. Because of the relative scarcity of PCs the selection of a specific PC for issue to the patient remains a challenging process. Regulatory agencies do not fully address these characteristics in their recommendations for prophylactic transfusions. The aim of the study was to analyse the effect of product-related factors in a real life setting, in order to determine which ones are the most relevant when selecting PCs for patients in prophylactic conditions. Two different endpoints are studied: the corrected count increment and the platelet transfusion time intervals.

Interventions

OTHERPlatelet concentrate transfusion

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Inpatients in the hematology department between January 2001 and December 2012 * Hematologic malignancy * At least one platelet transfusion (with platelet count ≤ 25 G/L) * Age 18 and over at time of first transfusion

Exclusion criteria

* More than one hematologic malignancy * Non-malignant haematological disorder

Design outcomes

Primary

Measure	Time frame	Description
Corrected count increment	24 hours post transfusion	Platelet increment corrected for platelet dose and body surface area

Secondary

Measure	Time frame	Description
Transfusion interval	7 days	Time interval to following platelet transfusion in days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026